These two different schedules were designed to evaluate EGFR’s effects in a highly injurious/inflammatory state (schedule 1) or a healed state (schedule 2), potentially allowing differential assessment of EGFR’s tumor-altering functions in the presence or absence of injury. This evidence concerns the gene EGFR and neoplasm.